Sven Andréasson
Senior Vice President, Corporate Development

Mr. Andréasson is Senior Vice President, Corporate Development with responsibility for identifying, prioritizing and evaluating new strategic opportunities that leverage the Novavax’ core strengths and growth initiatives. Mr. Andréasson joined Novavax in June 2014 and he brings a long history of experience in biopharmaceutical operations, executive management and strategic development from his many years in the industry. From 2012 to 2013 he served as the Chief Executive Officer of Isconova AB in Uppsala, Sweden, a leading international vaccine adjuvant company acquired by Novavax in 2013, currently operating as Novavax AB. Prior to his role at Novavax AB, Mr. Andréasson served as the Chief Executive Officer of Beta-Cell NV in Brussels, Belgium from 2008 to 2012 and as Chief Executive Officer of Active Biotech AB in Lund, Sweden from 1999 to 2008. Mr. Andréasson spent a number of years in roles inside Pharmacia Corporation including: President of Pharmacia SA, France, President of KabiPharmacia International and President of Pharmacia Arzneimittel GmbH, Germany. Mr. Andréasson received his Bachelour of Science degree in Business Administration and Economics from the Stockholm School of Economics, Sweden.